Atterocor names new CMO
This article was originally published in Scrip
Executive Summary
Atterocor, a company developing drugs for adrenal cancer, has named Dr Pharis Mohideen chief medical officer. He will lead all clinical strategies and activities, including overseeing the development of ATR-101, the company's investigational therapy for the treatment of adrenocortical carcinoma (ACC). Prior to joining Ann Arbor, Michigan-based Atterocor, Dr Mohideen was vice-president of clinical development at Shionogi.